<DOC>
	<DOCNO>NCT00331188</DOCNO>
	<brief_summary>The main objective study determine efficacy early administration Sanvar® combination endoscopic treatment control acute variceal bleeding .</brief_summary>
	<brief_title>Use Sanvar® With Endoscopic Treatment Control Acute Variceal Bleeding</brief_title>
	<detailed_description>This single-arm open-label clinical study historical control use Sanvar® ( vapreotide ) administer 5 day patient acute variceal bleeding due portal hypertension . Cirrhotic patient history acute hematemesis and/or melena admit emergency unit meeting eligibility criterion receive , soon possible admission ( within maximum 24 hour onset hemorrhage within 6 hour admission ) , Sanvar® ( vapreotide acetate ) 50 µg IV bolus follow IV continuous infusion 50 µg/h 5 day . The diagnostic therapeutic endoscopy perform soon possible initiation study drug infusion , 12 hour patient 's admission study center . A final follow perform Day 42 . Patients source bleeding determine endoscopy due cause portal hypertension ( e.g . gastric ulcer ) replace . In addition , case study medication discontinue patient receive standard treatment accord cause bleeding . These patient follow safety . *Note : There provision study expand access program .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Vapreotide</mesh_term>
	<criteria>Female male cirrhotic patient age 18 75 year . Hematemesis and/or melena ( suspect cause portal hypertension ) Time interval &lt; =24 hour onset initial hemorrhage initiation study drug infusion . Time interval &lt; =6 hour admission initiation study drug infusion . Anticipated time interval &lt; =12 hour admission end therapeutic endoscopy . Unequivocal history cirrhosis , either document least one classical clinical sign ( abdominal collateral venous circulation , firm liver sharp low liver edge , presence spider naevi , and/or ascites ) , biochemical and/or DopplerUS sign . Written inform consent obtain patient his/her relative ( ) Patient previously include study prior bleed episode . Patients treat vasoactive drug octreotide , vasopressin analogue current episode bleeding . Hepatic encephalopathy Grade IV . Balloon tamponade already position admission . Known ChildPugh score &gt; =13 Pregnant breastfeed woman . Known diffuse hepatocellular carcinoma . Known complete portal venous thrombosis . Bleeding esophageal varix within previous 6 week . Patient currently enrol another therapeutic study , and/or participate another clinical study , within previous 6 week . Known allergy somatostatin somatostatin analogue . Previous portosystemic shunt ( TIPS ) orthotopic liver transplantation . Patient known cancer . Patient know chronic renal failure ( serum creatinine &gt; 1.5 mg/dl ) . Severe concomitant disease judge Investigator incompatible evaluation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Esophageal Variceal Bleeding</keyword>
	<keyword>Portal Hypertension</keyword>
	<keyword>Hepatic Cirrhosis</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>Somatostatin Analog</keyword>
	<keyword>Vapreotide</keyword>
	<keyword>Acute Esophageal Variceal Bleeding</keyword>
</DOC>